Novaral Cosentyx first-line treatment

Novartis recently released data from two key international Phase 3 studies, which showed that Cosentyx (Chinese commodity names: good, common name: secukinumab, Skuchiyu monomatics, commonly known as "Sukin monomatics") provide rapid and powerful skin plaque removal and significantly improve quality of life in children and adolescents between the ages of 6 and 18.Psoriasis affects children far beyond the skin and can lead to a deterioration in the quality of life, which can have a lasting impact on this vulnerable group of patients. The results are encouraging and show that Cosentyx rapidly reduces the burden of symptoms with good safety in this vulnerable group of patients, and that the drug will provide a much-needed treatment option for the pediatric patient population.In early August, Cosentyx was approved by the European Union to treat children and adolescents with moderate to severe plaque psoriasis between the ages of 6 and 18. In terms of medication, the recommended dose for children weighing <50 kg is 75 mg (no lower weight limit) and for children weighing ≥50 kg is 150 mg (starting at 150 mg, which can be increased to 300 mg if required). In the U.S., Cosentyx's applications for patients of the same age group have been accepted by the FDA.
Children with psoriasis have a worse quality of life than their peers because of symptoms such as itching and fatigue, in addition to feeling humiliated. These, in turn, affect their emotional health and performance at school. With this EU approval, Cosentyx will provide a first-line system therapy for children with psoriasis in Europe. Currently, Cosentyx has approved four adaptations, and Novartic plans to expand to 10 over the next decade.The two phase III international studies of children and adolescents aged 6-18 were published: a study of open labels, arms, parallel groups, moderate to severe plaque psoriasis in multiple centers, and a study of randomized, double-blind, placebo, and etanercept-controlled severe plaque psoriasis. In the study, Cosentyx's dosing program was strated by weight. Studies have shown that both low-dose (75-150 mg) and high-dose (75-300 mg) Cosentyx are very effective in rapidly improving skin symptoms and quality of life and are safe for up to 52 weeks.In children with moderate to severe plaque-type psoriasis, low-dose Cosentyx has a fast, powerful skin plaque removal effect: 93% of patients achieve PASI 75 remission in the 12th week of treatment (psoriasis area and severity index improved by 75% relative to baseline), and 69% of patients reach P at the 12th week ASI 90 remission (90 per cent improvement), 88 per cent of patients reached PASI 90 remission at week 24, and 59.5 per cent of patients achieved complete skin loss removal (PASI 100) at week 12 and 67 per cent reached PASI 100 remission at week 24. In patients with severe psoriasis, low-dose Cosentyx ensures continuous skin loss removal until week 52, with 75% of patients reaching PASI 90 remission. Patients with severe psoriasis showed differences in PASI 75 as early as week 4 and patients with moderate to severe psoriasis as early as week 2.Half of children with moderate to severe plaque psoriasis had been completely relieved of the symptom burden of psoriasis by 12 weeks ago, according to the Children's Dermatological Quality of Life Index (CDLQI) 0/1 response. In children with severe plaque-type psoriasis treated with low doses of Cosentyx, 44.7% of patients were fully remissioned at week 12 and 60.6% at week 52. The safety characteristics of low-dose and high-dose Cosentyx are similar and consistent with established adult psoriasis adaptations. No new safety signals were observed in children.Psoriasis is a lifelong systemic inflammatory disease that seriously affects the physical and emotional quality of life of patients. One third of cases of psoriasis begin in childhood, with the most common onset occurring during adolescence. Moderate to severe psoriasis affects more than 350,000 children worldwide and can have a "far more profound" effect on children, with the physical and psychological burden of psoriasis disrupting important growth. Between 1970 and 2000, the incidence of psoriasis in children in the United States more than doubled, and the incidence of psoriasis increased in several countries. Only a few approved treatment options are available, and unsealed medical needs remain high.Cosentyx is the first all-human monoclonal antibody drug specific to target the suppression of interletin-17A (IL-17A), which selectively targets the activity of the circulating IL-17A, reduces immune system activity and improves disease symptoms. Studies have revealed that IL-17A played an important role in driving the body's immune response to a variety of autoimmune diseases, including psoriasis arthritis (PsA), plaque-type psoriasis (PsO), strong straight spinal inflammation (AS), radiologically negative mid-axis spinal arthritis (nr-axSpA).Cosentyx was approved for listing in January 2015 and has now been approved for four adaptations (PsO, PsA, AS, nr-axSpA). Cosentyx is supported by strong clinical evidence, including five years of data from the top three adaptations (PsO, PsA, AS) and data from real-world evidence. These data reinforce Cosentyx's unique position as a fast and long-lasting comprehensive treatment across axSpA, PsA, and psoriasis diseases. Since its launch, more than 340,000 patients worldwide have been treated with Cosentyx.In China, Cosentyx ® was approved by the National Drug Administration (NMPA) at the end of April for routine treatment of adult patients with severe spina blinitis (AS). This is the second adaptive condition approved in China following the approval in March 2019 for the treatment of moderate to severe plaque psoriasis (PsO) and the first and only white mesothemoid inhibitor approved for the treatment of severe spina brysitis (AS) in China®.In mid-June, Cosentyx ® approved in China ® his own handwriting. As an upgraded version of the® pre-charged injection needle, the good ®self-feeling pen® will optimize the original method of administration in all directions, "one-touch" operation will reduce the difficulty of injection, improve the patient's treatment experience, while effectively avoiding drug waste caused by operational errors, for China's light and heavy plaque psoriasis patients and patients with severe spina brypsitis to bring more convenient, safe and efficient treatment experience. (Bio Valley)original source: Novartis presents latest Phase III data data ® Cosentyx® as a first-line systemic treatment in pediatric psoriasis